.
What is AbbVie stock doing on Friday?
On Friday, AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing 156-week Phase 3 open-label extension study evaluating the long-term safety and tolerability of oral atogipan for the prevention of migraine in patients with chronic or flare-up migraine. According to Benzinga Pro, the company's shares were trading lower with a volume of 3.9 million shares in mid-pan compared to an average volume of 5.6 million shares. Also Read: AbbVie Raises Long-Term Outlook for Immunology Drugs Even as Q4 Revenue Falls
English 
Chinese